1. GIPL completes phase one of heartworm breath test research. 2. Over 100 samples validated for earlier heartworm detection. 3. CEO emphasizes the importance of early detection in canine health. 4. Research led by experienced veterinary professionals. 5. Further research planned to confirm breath markers and expand testing.
The successful completion of the first research phase indicates potential for innovative diagnostic solutions, thereby attracting interest from investors. Similar companies have seen stock increases after announcing advancement in medical technology.
The research progress showcases GIPL's potential to disrupt the veterinary diagnostics market, appealing to investors searching for innovative health solutions.
GIPL's future impact hinges on regulatory approval and market acceptance of the new diagnostic tool, which could take time. Historical examples show companies often experience price growth over years following successful product developments.
MAITLAND, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Global Innovative Platforms Inc. (OTC:GIPL) today announced completion of the first phase of its research into breath-based diagnostics for detecting heartworm disease in dogs. The initial study included over 100 samples and focused on validating data to support development of a point-of-care, non-invasive test designed to detect infection earlier than the current industry standard of six months.
"Early detection is the key to protecting dogs from the serious effects of heartworm," said Andrew Brown, CEO of Global Innovative Platforms. "Our goal is to create a simple and non-invasive breath test that veterinary teams can use to potentially identify infections earlier than available heartworm diagnostic tests. If successful, earlier detection could enable veterinarians and owners the opportunity to intervene sooner, potentially helping dogs live healthier, longer lives."
The American Heartworm Society currently recommends testing dogs beginning at six months of age and annually thereafter. At present, there is no point-of-care diagnostic widely available that can reliably identify heartworm infection until the infection has been present for approximately six months or more in that dog.
Dr. Lindsay Starkey, DVM, PhD, DACVM, who is leading the research team at Global Innovative, commented: "I am always looking for new ways to improve animal health. Working on this project is exciting, and the initial data is encouraging. We look forward to continuing the research and exploring how breath analysis may contribute to earlier, more effective detection. Dr. Starkey worked alongside Drs. Byron Blagburn and Sarah Zohdy, both of whom were pioneers in the initial heartworm breath research starting in 2017.
Additional on-site testing was overseen by parasitologist Dr. Elyssa Campbell, PhD. The twelve-month study period involved collecting and analyzing over 100 breath samples under her supervision. Dr. Campbell commented "I'm grateful to be working with such a talented team and committed to continuing this work. The data we have gathered show a lot of promise and reinforces our belief that breath analysis could be a significant step forward in veterinary diagnostics."
Global Innovative is planning further research seeking to confirm heartworm breath markers and expand testing. If successful, the company may pursue development of a proprietary diagnostic device with the goal of allowing for it to have the potential to detect multiple conditions through a single breath analysis.
About Global Innovative Platforms Inc.
Global Innovative Platforms Inc. (OTC:GIPL) is focused on advancing animal health through non-invasive breath analysis and air quality technology. The Company's Animal Health Division is developing diagnostic tools designed to detect disease, monitor treatment effectiveness, and assess environmental and food-related health risks.
Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially, including but not limited to risks related to research and development outcomes, regulatory approvals, market acceptance, and other factors described in Global Innovative's filings with the SEC. See the Company's Annual Report Form 10-K for filed at www.sec.gov for other risk factors which investors should consider. These forward-looking statements speak only as to the date of this announcement and cannot be relied upon as a guide to future performance. Global Innovative expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.
Media Contact:
Andrew Brown, CEO
Andrew@GIPLinc.com
321.230.3739
